IRIS Accounts Production v24.1.0.578 08039863 Board of Directors 1.1.23 31.12.23 31.12.23 false true false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh080398632022-12-31080398632023-12-31080398632023-01-012023-12-31080398632021-12-31080398632022-01-012022-12-31080398632022-12-3108039863ns15:EnglandWales2023-01-012023-12-3108039863ns14:PoundSterling2023-01-012023-12-3108039863ns10:Director12023-01-012023-12-3108039863ns10:PrivateLimitedCompanyLtd2023-01-012023-12-3108039863ns10:SmallEntities2023-01-012023-12-3108039863ns10:AuditExempt-NoAccountantsReport2023-01-012023-12-3108039863ns10:SmallCompaniesRegimeForDirectorsReport2023-01-012023-12-3108039863ns10:SmallCompaniesRegimeForAccounts2023-01-012023-12-3108039863ns10:FullAccounts2023-01-012023-12-3108039863ns10:OrdinaryShareClass12023-01-012023-12-3108039863ns10:Director22023-01-012023-12-3108039863ns10:RegisteredOffice2023-01-012023-12-3108039863ns5:CurrentFinancialInstruments2023-12-3108039863ns5:CurrentFinancialInstruments2022-12-3108039863ns5:ShareCapital2023-12-3108039863ns5:ShareCapital2022-12-3108039863ns5:RetainedEarningsAccumulatedLosses2023-12-3108039863ns5:RetainedEarningsAccumulatedLosses2022-12-3108039863ns5:CostValuation2022-12-3108039863ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-12-3108039863ns5:CurrentFinancialInstrumentsns5:WithinOneYear2022-12-3108039863ns10:OrdinaryShareClass12023-12-31
REGISTERED NUMBER: 08039863 (England and Wales)















UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 DECEMBER 2023

FOR

GH PHARMA (UK) LTD

GH PHARMA (UK) LTD (REGISTERED NUMBER: 08039863)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


GH PHARMA (UK) LTD

COMPANY INFORMATION
FOR THE YEAR ENDED 31 DECEMBER 2023







DIRECTORS: R Ricciardi
W K Wong





REGISTERED OFFICE: Charlton House
Dour Street
DOVER
Kent
CT16 1BL





REGISTERED NUMBER: 08039863 (England and Wales)





ACCOUNTANTS: McCabe Ford Williams
Chartered Accountants
Charlton House
Dour Street
DOVER
Kent
CT16 1BL

GH PHARMA (UK) LTD (REGISTERED NUMBER: 08039863)

BALANCE SHEET
31 DECEMBER 2023

2023 2022
Notes £    £    £    £   
FIXED ASSETS
Investments 4 89 89

CURRENT ASSETS
Stocks 2,412 55,917
Debtors 5 353,086 187,119
Cash at bank 615,212 1,212,829
970,710 1,455,865
CREDITORS
Amounts falling due within one year 6 923,642 1,420,486
NET CURRENT ASSETS 47,068 35,379
TOTAL ASSETS LESS CURRENT
LIABILITIES

47,157

35,468

CAPITAL AND RESERVES
Called up share capital 7 2 2
Retained earnings 47,155 35,466
SHAREHOLDERS' FUNDS 47,157 35,468

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2023 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 9 April 2024 and were signed on its behalf by:





W K Wong - Director


GH PHARMA (UK) LTD (REGISTERED NUMBER: 08039863)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2023

1. STATUTORY INFORMATION

GH Pharma (UK) Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

The presentation currency of the financial statements is the Pound Sterling (£).


2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Preparation of consolidated financial statements
The financial statements contain information about GH Pharma (UK) Ltd as an individual company and do not contain consolidated financial information as the parent of a group. The company is exempt under Section 399(2A) of the Companies Act 2006 from the requirements to prepare consolidated financial statements.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Investments in subsidiaries
Investments in subsidiary undertakings are recognised at cost.

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Foreign currencies
Assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate of exchange ruling at the date of transaction. Exchange differences are taken into account in arriving at the operating result.

GH PHARMA (UK) LTD (REGISTERED NUMBER: 08039863)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 DECEMBER 2023

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2022 - 2 ) .

4. FIXED ASSET INVESTMENTS
Shares in
group
undertakings
£   
COST
At 1 January 2023
and 31 December 2023 89
NET BOOK VALUE
At 31 December 2023 89
At 31 December 2022 89

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Trade debtors 187,984 30,530
Amounts owed by group undertakings 164,303 145,894
Other debtors and prepayments 799 976
Tax - 9,719
353,086 187,119

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Trade creditors 861,236 1,418,886
Tax 44 -
Social security and other taxes 11,695 -
Other creditors 50,667 1,600
923,642 1,420,486

7. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2023 2022
value: £    £   
2 Ordinary £1 2 2

8. RELATED PARTY DISCLOSURES

At the year end a loan of £164,303 (2022 - £145,894) was due from Global Harvest Pharmaceuticals (Ireland) Limited, a subsidiary of the company. During the year, sales of £NIL (2022 - £48,456) were made to the subsidiary and £11,139 (2022 - £30,299) was outstanding at the year end. During the year purchases of £6,976 (2022 - £NIL) were made from the subsidiary and this amount was outstanding at the year end.